Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence

FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells

(2013) Jiechuang Su et al.   BIOCHEMICAL JOURNAL

Zinc Finger Nuclease Mediated Knockout of ADP-Dependent Glucokinase in Cancer Cell Lines: Effects on Cell Survival and Mitochondrial Oxidative Metabolism

(2013) Susan Richter et al.   PLoS One

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

(2013) Thomas Gaj et al.   TRENDS IN BIOTECHNOLOGY

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

(2012) Mark J McKeage et al.   BMC CANCER

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer

(2012) K. Hendricksen et al.   JOURNAL OF UROLOGY

Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs

(2011) Francis W. Hunter et al.   BIOCHEMICAL PHARMACOLOGY

The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia

(2011) J. Wang et al.   CLINICAL CANCER RESEARCH

Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways

(2011) Nadine Rohwer et al.   DRUG RESISTANCE UPDATES

Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases

(2011) T. Gutschner et al.   GENOME RESEARCH

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases

(2011) J. Hauschild et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

(2011) R. Le Floch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Skyline: an open source document editor for creating and analyzing targeted proteomics experiments

(2010) Brendan MacLean et al.   BIOINFORMATICS

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

(2010) C. P. Guise et al.   CANCER RESEARCH

Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

(2010) William A Denny   Future Oncology

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02

(2010) Lester J. Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Roles of Cytochrome P450 Reductase in Mitomycin c Redox Cycling and Cytotoxicity

(2010) Y. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Genome editing with engineered zinc finger nucleases

(2010) Fyodor D. Urnov et al.   NATURE REVIEWS GENETICS

BAKandBAXdeletion using zinc-finger nucleases yields apoptosis-resistant CHO cells

(2009) Gregory J. Cost et al.   BIOTECHNOLOGY AND BIOENGINEERING

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

(2009) R. S. Singleton et al.   CANCER RESEARCH

Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly

(2009) H. J. Kim et al.   GENOME RESEARCH

Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitroseco-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents

(2009) Moana Tercel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Measurement of cytochrome P450 and NADPH–cytochrome P450 reductase

(2009) F Peter Guengerich et al.   Nature Protocols

Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases

(2009) Aron M. Geurts et al.   SCIENCE

Progress and prospects: Zinc-finger nucleases as gene therapy agents

(2008) D Carroll   GENE THERAPY

Design of anticancer prodrugs for reductive activation

(2008) Yu Chen et al.   MEDICINAL RESEARCH REVIEWS

Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification

(2008) Morgan L. Maeder et al.   MOLECULAR CELL

Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases

(2008) Yannick Doyon et al.   NATURE BIOTECHNOLOGY

Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases

(2008) Xiangdong Meng et al.   NATURE BIOTECHNOLOGY

Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases

(2008) Y. Santiago et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficient gene targeting in Drosophila by direct embryo injection with zinc-finger nucleases

(2008) K. J. Beumer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA